Conference Coverage
Latest News
Jul 15, 2026 | Opinion
University of Florida chief residents discuss mentorship, self-care, and residency success
Pivotal phase 3 trial launches of rinzimetostat plus darolutamide in mCRPC
Jul 15, 2026
First Assist: Early Cystectomy in Non–Muscle Invasive Bladder Cancer, with Matvey Tsivian, MD
Jul 15, 2026
Ryan K. Flannigan, MD, discusses sustained-release lidocaine for chronic scrotal content pain
Jul 14, 2026
Genomic Prostate Score may help refine risk assessment in localized prostate cancer
Jul 14, 2026
Advertisement
Shorts
0:42
Closing the gap: Urologists and female sexual health
an hour ago
by
Melissa Moran, DO
0:54
Testosterone and prostate cancer risk: A balanced message
a day ago
by
Helen L. Bernie, DO, MPH
1:03
Beyond cisplatin eligibility: A new MIBC standard
2 days ago
by
María Natalia Gandur Quiroga, MD, MSc
0:39
Anatomy vs function: What reconstruction really means
5 days ago
by
Sasha Vereecken, RN
1:40
The role of focal therapy in an evolving prostate cancer landscape
6 days ago
by
Joy Maulik, CRNP(+1 more)
0:42
Michael Uy, MD on the impact of unmet social needs in kidney stone disease
7 days ago
by
Michael John Mari Talagsa Uy, MD
2:00
Urocross: The case for a retrievable BPH device
8 days ago
by
Kevin T. McVary, MD
0:51
Ravi Munver, MD, on AI-guided treatment planning with the HYDROS system
9 days ago
1:42
What urologists need to know before using Break Wave
12 days ago
by
Ben H. Chew, MD, MSc
0:46
Hans Arora, MD, PhD, on the most critical factor in surgical team performance
13 days ago
by
Hans Arora, MD, PhD
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Podcasts
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Ravi Munver, MD, discusses a propensity score–matched comparison of the AquaBeam system and the second-generation AI-powered HYDROS platform for BPH.
Amy Pearlman, MD, is joined by Larry I. Lipshultz, MD, and Dolores J. Lamb, PhD, to discuss the evolving role of semen analysis, laboratory diagnostics, and emerging genetic technologies in the evaluation of male infertility.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab's (Keytruda) expanded approval shifts the perioperative MIBC conversation from cisplatin eligibility to optimal systemic strategy, according to María Natalia Gandur Quiroga, MD, MSc.
Daniel J. George, MD reviews the data behind the FDA approval of capivasertib for PTEN-deficient metastatic prostate cancer.
CVAC and FANS reflect different surgical philosophies—dusting vs fragmentation—with distinct ergonomic trade-offs and shared intrarenal pressure risks that urologists must actively monitor, according to Krambeck.
This decision extends the indication for pembrolizumab plus enfortumab vedotin to all patients with MIBC who are candidates for cystectomy.
In this episode, Badrinath R. Konety, MBBS, walks through key recommendations from the 2026 AUA/SUO Early Detection of Prostate Cancer Guideline amendment.
The phase 1 trial is assessing the safety and preliminary antitumor activity of actinium (225Ac) rhPSMA-10.1 injection.
FDA clearance of the IND for UGN-501 paves the way for a first-in-human phase 1 trial evaluating its safety and feasibility in patients with NMIBC.
The findings suggest that a significant proportion of participants may benefit from discontinuing tamsulosin.
Advertisement
Sender Herschorn, BSc, MDCM, FRCSC, discusses a subgroup analysis of the COURAGE trial showing that vibegron provided comparable efficacy and favorable safety in men aged 75 years and older with persistent OAB symptoms receiving pharmacotherapy for BPH.
In this episode, Anup A. Vora, MD, discusses patient selection for focal therapy in localized prostate cancer, the role of precision medicine, and how advanced practice providers are helping deliver comprehensive, patient-centered GU oncology care.
Urocross produced deepening IPSS improvement through 24 months post-retrieval, with Kevin T. McVary, MD, FACS, attributing a post-removal symptomatic boost to completed prostatic remodeling and full preservation of future treatment options.
A recent meta-analysis suggests that the Prolaris combined clinical risk score is prognostic across NCCN risk groups in men with localized prostate cancer.
Amy Pearlman, MD, and guests discuss how to address unmet needs in bladder care through telehealth, education, and behavioral interventions.
Advertisement
Advertisement
Trending on Urology Times
1
Genomic Prostate Score may help refine risk assessment in localized prostate cancer
2
Ryan K. Flannigan, MD, discusses sustained-release lidocaine for chronic scrotal content pain
3
Ravi Munver, MD, highlights study of first- and second-generation Aquablation systems
4
Pivotal phase 3 trial launches of rinzimetostat plus darolutamide in mCRPC
5